Clinical trial
Fractional Flow Reserve-guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment Versus Optimal Medical Treatment Alone in Patients with Stable Coronary Artery Disease - FAME II, a 10-year Follow-up Study.
NCT06159231 is registered in ClinicalTrials.gov with CoreAalst BV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Fractional Flow Reserve-guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment Versus Optimal Medical Treatment Alone in Patients with Stable Coronary Artery Disease - FAME II, a 10-year Follow-up Study.
- Lead sponsor
- CoreAalst BV
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 25, 2023
- Completion date
- May 15, 2024
- Enrollment
- 888 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.